Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.75 |
| ▸ | MPO | P05164 | 6/20 | 0.73 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.73 |
| ▸ | TEAD4 | Q15561 | 2/20 | 0.71 |
| ▸ | YAP1 | P46937 | 1/20 | 0.71 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.71 |
| ▸ | TAS2R14 | Q9NYV8 | 5/20 | 0.69 |
| ▸ | AURKA | O14965 | 1/20 | 0.69 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.69 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.68 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.68 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.64 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | GMNN | O75496 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | TTR | P02766 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flufenamic Acid SCHEMBL17497 | 1.00 | RXFP1 (0.75) | RXFP1MPOGRIK1TEAD4YAP1 | |
| Flufenamic Acid SCHEMBL11524554 | 0.99 | RXFP1 (0.73) | RXFP1MPOGRIK1TEAD4YAP1 | |
| Flufenamic Acid SCHEMBL9845499 | 0.99 | RXFP1 (0.73) | RXFP1MPOGRIK1TEAD4YAP1 | |
| SCHEMBL8416271 | 0.92 | RXFP1 (0.81) | RXFP1MPOGRIK1 | |
| Flufenamic Acid SCHEMBL10531046 | 0.89 | MPO (0.67) | RXFP1MPOGRIK1TEAD4YAP1 | |
| SCHEMBL19002050 | 0.89 | TAS2R14 (0.62) | RXFP1MPOGRIK1TEAD4YAP1 | |
| SCHEMBL11330727 | 0.88 | TAS2R14 (0.82) | RXFP1MPOGRIK1TAS2R14AKR1C3 | |
| SCHEMBL19657901 | 0.87 | RXFP1 (0.70) | RXFP1MPOGRIK1TEAD4YAP1 | |
| SCHEMBL9522037 | 0.87 | YAP1 (0.74) | RXFP1MPOGRIK1TEAD4YAP1 | |
| SCHEMBL12851592 | 0.87 | RXFP1 (0.78) | RXFP1MPOTEAD4YAP1TEAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 863 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121577796-A | ROS (reactive oxygen species) high-efficiency synchronous identification system combining multiple molecular probes and application thereof | 上海大学 | 2026-02-27 | — | — | CN | claimed |
| US-12485102-B2 | Methods and compositions for treating cancer | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2025-12-02 | — | — | US | claimed |
| US-20250161330-A1 | METHODS OF MEDICAL TREATMENT WITH SUR1-TRPM4 CHANNEL INHIBITORS | REMEDY PHARMACEUTICALS, INC. (US) | 2025-05-22 | — | — | US | claimed |
| CN-119997813-A | Emulsifiable concentrate with lactone-based solvent system | 巴斯夫欧洲公司 | 2025-05-13 | — | — | CN | claimed |
| CN-119744863-A | Bactericide composition and application thereof | 江苏中旗科技股份有限公司 | 2025-04-04 | — | — | CN | claimed |
| CN-119666767-A | Environment-friendly detection method for trace heavy metal antimony in water | 浙江工业大学 | 2025-03-21 | — | — | CN | claimed |
| CN-119110681-A | Emulsifiable concentrate with (substituted) benzaldehyde-based solvent system | 巴斯夫欧洲公司 | 2024-12-10 | — | — | CN | claimed |
| CN-112770764-B | Methods of treating infections using bacteria | 因达普特斯治疗有限公司 | 2024-12-03 | — | — | CN | claimed |
| CN-118973395-A | Methods and compositions for controlling pests on perennial plants | 环球化学股份有限公司 | 2024-11-15 | — | — | CN | claimed |
| CN-118870974-A | Fungicidal combinations and methods for controlling phytopathogenic fungi | UPL有限责任公司 | 2024-10-29 | — | — | CN | claimed |
| EP-4153870-A2 | CYLINDER PISTON END CAP AND LOCK MECHANISM AT FULL SAFE LOAD THAT CAN BE INTEGRATED INTO HYDRAULIC AND PNEUMATIC CYLINDERS | Ozel, Ali (TR) | 2023-03-29 | — | — | EP | claimed |
| WO-2023023702-A1 | MEDICATED SUPPLEMENT FOR ANIMALS | Medical Ethics Pty Ltd (AU) | 2023-03-02 | — | — | WO | claimed |
| US-20220403414-A1 | NOVEL AAV VARIANT | WUXI APPTEC SHANGHAI CO LTD (CN) | 2022-12-22 | — | — | US | claimed |
| CN-218085817-U | Bicycle saddle with adjustable multi-angle | 唐山辰阳运动器材有限公司 | 2022-12-20 | — | — | CN | claimed |
| CN-217904673-U | Coal mine underground double-link communication system | 天津华宁电子有限公司 | 2022-11-25 | — | — | CN | claimed |
| US-20220281889-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2022-09-08 | — | — | US | claimed |
| EP-4045664-A1 | A NOVEL AAV VARIANT | Wuxi Apptec (Shanghai) Co., Ltd. (CN) | 2022-08-24 | — | — | EP | claimed |
| US-20220088039-A1 | METHODS OF MEDICAL TREATMENT WITH SUR1-TRPM4 CHANNEL INHIBITORS | BIOGEN CHESAPEAKE LLC (US) | 2022-03-24 | — | — | US | claimed |
| CN-114172712-A | Automatic upgrading equipment between networks | 柴国丽 | 2022-03-11 | — | — | CN | claimed |
| US-20220031768-A1 | METHODS OF TREATMENT OF INFECTIONS USING BACTERIA | INDAPTUS THERAPEUTICS, INC. | 2022-02-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281889-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE7A, PDE12 | RXFP1 2669/4885MPO 195/4885GRIK1 4038/4885 |
| US-12485102-B2 | Methods and compositions for treating cancer | PPARG, FFAR1, PPARA | RXFP1 2201/4885MPO 3889/4885GRIK1 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.